9 Meters Bio (NMTR) in the spotlight

COVID-related delays and expectations moving forward

9 Meters Bio (NMTR) shared yesterday that their topline results for Phase 2 in Short Bowel Syndrome (SBS) will be pushed back to Q2 2022. This is the second delay, as the original results were expected by year-end 2021. That was pushed to Q1 and now Q2. The company mentioned the Omicron spike as the cause of the delay. Although the COVID excuse may be v…